Loading…
Veracyte, Inc. is projected to rise to $84.04 by 2027, a +41% move from its current price of $59.78. VCYT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $58.29 | $59.84 | $61.43 | +0.09% |
| Aug 2 | $57.71 | $59.89 | $62.16 | +0.19% |
| Aug 3 | $57.29 | $59.95 | $62.74 | +0.28% |
| Aug 4 | $56.94 | $60.01 | $63.24 | +0.38% |
| Aug 5 | $56.64 | $60.06 | $63.69 | +0.47% |
| Aug 6 | $56.38 | $60.12 | $64.11 | +0.57% |
| Aug 7 | $56.14 | $60.18 | $64.50 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $56.14 | $60.18 | $64.50 | +0.66% |
| Week 2 | $54.91 | $60.57 | $66.82 | +1.33% |
| Week 3 | $54.07 | $60.98 | $68.77 | +2.00% |
| Week 4 | $53.42 | $61.38 | $70.52 | +2.68% |
| Week 5 | $52.90 | $61.79 | $72.16 | +3.36% |
| Week 6 | $52.47 | $62.20 | $73.72 | +4.04% |
| Week 7 | $52.10 | $62.61 | $75.23 | +4.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
It also provides the nCounter analysis system services.
The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc. (VCYT) is a healthcare stock with a current price of $56.61. The company has a market cap of $4.52B and is ranked 1380 by market capitalization. These fundamentals sit alongside a long-run price forecast that envisions bullish upside across multiple years, with meaningful increases in average prices from 2027 through 2050 and beyond.
The forecast shows year-by-year upside, with the 2027 average at $80.16, 2028 at $96.46, 2029 at $113.58, and 2030 at $123.05. From 2040 onward, the model projects substantial gains, culminating in a 2050 average of $1,076.94. These estimates imply a sustained bull trajectory over the coming years, though they carry the usual uncertainty inherent in price forecasts.
A major floor 49.8% below — a decisive break under it would weaken the trend.
The nearest floor, 14.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.2% away) — a breakout level to watch.
A major ceiling 11.1% above — clearing it would confirm fresh momentum.
Key VCYT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VCYT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $56.67 | Buy | $57.44 | Buy |
| MA 10 | $57.52 | Buy | $57.39 | Buy |
| MA 20 | $57.58 | Buy | $56.95 | Buy |
| MA 50 | $53.22 | Buy | $52.85 | Buy |
| MA 100 | $43.62 | Buy | $47.67 | Buy |
| MA 200 | $41.83 | Buy | $42.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.37 | Neutral |
| Stoch RSI (14) | 80.80 | Sell |
| CCI (20) | 120.91 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.50 | Sell |
| ROC (12) | 5.58 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.41 | Buy |
| Ultimate (7,14,28) | 54.40 | Neutral |
| Momentum (10) | 0.56 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 56.21 | Buy |
| ADX (14) | 20.52 | Buy |
| ATR (14) | 1.34 | Info |
The 30-day technical picture for Veracyte is bullish. RSI14 is 60, and near-term momentum supports a positive tilt. The stock trades around the 50-day and 200-day moving averages, with SMA50 at $51.49 and SMA200 at $41.29.
Immediate support sits at $47.33 and resistance at $60.49, with the most recent 30-day range spanning $0.01? to $0.00? (the observable range is $48.01–$66.76). The 30-day range high and low indicate upside potential within this frame.
The stock’s volatility framework shows an annualized volatility of 50%, underscoring the higher-risk, higher-reward profile typical of mid-cap healthcare equities.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.01 | $59.78 | $86.34 | 0% | Neutral | |
| $67.26 | $84.04 | $110.88 | +41% | Bullish | |
| $78.34 | $100.57 | $137.59 | +68% | Bullish | |
| $89.67 | $117.71 | $165.66 | +97% | Bullish | |
| $95.20 | $127.44 | $183.67 | +113% | Bullish | |
| $115.03 | $156.77 | $230.65 | +162% | Bullish | |
| $146.28 | $202.68 | $303.79 | +239% | Bullish | |
| $170.38 | $239.77 | $365.48 | +301% | Bullish | |
| $188.51 | $269.21 | $416.76 | +350% | Bullish | |
| $202.67 | $293.54 | $460.98 | +391% | Bullish | |
| $350.69 | $541.34 | $902.88 | +806% | Bullish | |
| $634.52 | $1,092.34 | $1,988.98 | +17.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.01 | $59.78 | $69.75 | +0.00% |
| August 2026 | $53.35 | $62.56 | $75.04 | +4.65% |
| September 2026 | $55.11 | $65.15 | $79.16 | +4.14% |
| October 2026 | $54.86 | $65.27 | $80.12 | +0.19% |
| November 2026 | $55.21 | $66.03 | $81.71 | +1.16% |
| December 2026 | $57.62 | $69.25 | $86.34 | +4.88% |
Click any year to see its month-by-month VCYT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Veracyte, Inc.'s 2026 outlook centres on $59.78, within a $30.01 to $86.34 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, VCYT could reach as high as $110.88, with a base case around $84.04 and support toward $67.26 — roughly +41% from $59.78. Momentum favours further upside here.
Expect VCYT to range from $78.34 to $137.59 through 2028. The $100.57 average target implies a +68% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The VCYT price prediction for 2029 points to an average of $117.71 (low $89.67, high $165.66) — a potential gain of +97% on today's $59.78. Momentum favours further upside here.
In 2030, VCYT is projected to trade between $95.20 and $183.67, averaging $127.44 — a potential gain of +113% from today's $59.78. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Veracyte, Inc.'s 2031 outlook centres on $156.77, within a $115.03 to $230.65 range. That is up +23% on the projected 2030 average. That marks a +162% change versus current levels. Momentum favours further upside here.
By 2032, VCYT could reach as high as $303.79, with a base case around $202.68 and support toward $146.28 — roughly +239% from $59.78. Buyers look set to stay in control over this stretch.
Expect VCYT to range from $170.38 to $365.48 through 2033. The $239.77 average target implies a +301% move from current prices. That is up +18% on the projected 2032 average. Momentum favours further upside here.
The VCYT price prediction for 2034 points to an average of $269.21 (low $188.51, high $416.76) — a potential gain of +350% on today's $59.78. Buyers look set to stay in control over this stretch.
In 2035, VCYT is projected to trade between $202.67 and $460.98, averaging $293.54 — a potential gain of +391% from today's $59.78. That is up +9% on the projected 2034 average. Momentum favours further upside here.
Veracyte, Inc.'s 2040 outlook centres on $541.34, within a $350.69 to $902.88 range. That is up +84% on the projected 2035 average. That marks a +806% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, VCYT could reach as high as $1,988.98, with a base case around $1,092.34 and support toward $634.52 — roughly +17.3x from $59.78. Momentum favours further upside here.
Investing $1,000 in VCYT today (≈ 16.728003 VCYT) could be worth
$18,272.73
+$17,272.73 (+1727%) by 2050 · US Dollar
Based on the average projected VCYT price of $1,092.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VCYTwould be worth at today's price.
$1,000 invested in VCYT on Jul 30, 2025 (≈ 41.718816 VCYT) would be worth
$2,493.95
+$1,493.95 (+149.4%) today · 2.49× · US Dollar
Based on a VCYT entry price of $23.97 vs. today's $59.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $57.88 | $1,032.83 | +3.3% |
| 1 month ago | $58.73 | $1,017.88 | +1.8% |
| 3 months ago | $33.09 | $1,806.59 | +80.7% |
| 6 months ago | $38.08 | $1,569.85 | +57.0% |
| 1 year ago | $23.97 | $2,493.95 | +149.4% |
| All time (5.0y) ago | $43.94 | $1,360.49 | +36.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VCYT forecast.
Our base-case forecast reaches $120.00 around 2030.
Implied market cap at $120.00: $9.58B
The multi-year price forecast presents bullish prospects across the horizon. In 2030, the avg price is $123.05 with a min of $92.61 and a max of $175.76, yielding an ROI of 117.4% and a bullish sentiment. The model projects continued upside in 2040, with an avg of $528.30, a min of $347.69, a max of $868.68, and an ROI of 833.2%.
By 2050, the avg is $1,076.94 with a min of $640.07 and a max of $1,927.80, corresponding to an ROI of 1802.4% and a bullish outlook.
Overall, the long-term forecast depicts substantial upside potential, but these are estimates and not guarantees. The bullish trajectory implies meaningful appreciation if the factors driving these projections hold, while investors should acknowledge the inherent uncertainty and the possibility of downside risks.
Tap a question to reveal the answer.
2030 avg $123.05, min $92.61, max $175.76, ROI 117.4%, sentiment bullish.
Forecast shows bullish sentiment from 2027 onward with rising averages to $123.05 by 2030, $528.30 by 2040, and $1,076.94 by 2050; these are estimates and not guarantees.
Yes. 2029 avg is $113.58, with a max of $158.58, indicating the potential to exceed $100 in the forecast horizon.
2040 avg $528.30, ROI 833.2%; 2050 avg $1,076.94, ROI 1802.4%.
Current price $56.61; Market Cap $4.52B; Rank 1380.
Veracyte, Inc. Community Discussion
0Share your Veracyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.